Jeevan Scientific Technology Reports Positive Financial Performance in Q1 2024

Jeevan Scientific Technology, a microcap company in the pharmaceutical industry, has recently announced its financial results for the quarter ending March 2024. The results, declared on August 9, 2024, have received a 'Sell' call from MarketsMOJO.

Despite this, Jeevan Scientific Technology has shown positive financial performance in the quarter, with a score improvement from 2 to 18 in the last 3 months. This is a significant improvement and reflects the company's efforts to drive growth and profitability.

One of the key factors contributing to this positive performance is the growth in Profit Before Tax less Other Income (PBT) which has increased by 355.81% year on year. The near-term trend for PBT is also very positive. Similarly, the Profit After Tax (PAT) has also shown a growth of 175.9% year on year, with a positive near-term trend.

The company's net sales for the quarter were at Rs 12.52 crore, the highest in the last five quarters. This reflects a positive trend in sales, with a growth of 20.50% year on year. The Operating Profit (PBDIT) for the quarter was also at its highest in the last five quarters, at Rs 3.40 crore. The Operating Profit Margin, which measures the company's efficiency, was also at its highest in the last five quarters at 27.16%.

Jeevan Scientific Technology has also shown a positive trend in its Profit Before Tax less Other Income (PBT) and Profit After Tax (PAT), with both being at their highest in the last five quarters. The company's Earnings per Share (EPS) have also increased to Rs 1.03, indicating a higher profitability and value creation for shareholders.

Overall, Jeevan Scientific Technology's financial results for the quarter ending March 2024 have shown a positive trend, with improvements in key financial metrics. This reflects the company's efforts to drive growth and profitability in the pharmaceutical industry.